4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
FDMT(NASDAQ:FDMT) EMERYVILLE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced senior leadership additions and changes that align with the Company’s focus on late-stage clinical trial and BLA execution and commercial readiness.
4DMT to Participate in Upcoming Investor Conferences
FDMTEMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.
4DMT Announces New Employment Inducement Grants
FDMTEMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
FDMTEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined expected upcoming milestones.
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
FDMTGoldman Sachs Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $44
FDMTBarclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $38
FDMTCORRECTION: 4D Molecular Therapeutics Q1 EPS $(0.86) Misses $(0.83) Estimate, Sales $14.00K Miss $382.57K Estimate
FDMT4D Molecular Therapeutics Q1 EPS $0.86 Beats $(0.83) Estimate, Sales $14.00K Miss $382.57K Estimate
FDMT4DMT Announces RMAT Designation Granted By FDA For 4D-150 For Treatment Of Diabetic Macular Edema
FDMTB of A Securities Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $40
FDMT4DMT Enrolls First Patient In 4FRONT-1 Phase 3 Clinical Trial Of 4D-150 For Wet AMD
FDMTChardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $28
FDMTRBC Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $35
FDMTForecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
FDMTHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
FDMT4D Molecular Therapeutics FY 2024 GAAP EPS $(2.98) Misses $(2.92) Estimate, Sales $37.000K
FDMTMorgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6
FDMTLeerink Partners Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $27
FDMTA Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
FDMTHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
FDMT4DMT Extends Cash Runway To 2028 With $506M, Plans Phase 3 Trials For 4FRONT-1 & 4FRONT-2 In Wet AMD, Develops Early-Stage DME And CF, Explores Partnerships And Strategic Financing
FDMTChardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $39 Price Target
FDMTHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
FDMTAnalyst Expectations For 4D Molecular Therapeutics's Future
FDMTRBC Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $39
FDMT